Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8917213 | 0.78 | MAOA (0.37) | SMN1; SMN2MAOAMAOBCHRNB2CHRNA4 | |
| SCHEMBL10120022 | 0.78 | LMNA (0.40) | LMNAHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL1452779 | 0.75 | PGR (0.38) | MAOAMAOBMEN1ALDH1A1KMT2A | |
| SCHEMBL15800627 | 0.72 | CA1 (0.42) | LMNAMEN1ALDH1A1KMT2AELANE | |
| SCHEMBL9544149 | 0.72 | TDO2 (0.36) | MAOAMAOBCHRNB2CHRNA4MEN1 | |
| Hydrochloric Acid SCHEMBL7609388 | 0.71 | HTR2A (0.42) | PPIALMNASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL27375941 | 0.69 | HTR2A (0.44) | PPIALMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL1451517 | 0.69 | PGR (0.38) | MAOAMAOBMEN1ALDH1A1KMT2A | |
| SCHEMBL17067722 | 0.68 | CNR1 (0.38) | HTTSMN1; SMN2 | |
| SCHEMBL31367791 | 0.68 | PPARD (0.36) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | NSUN2, HCCS, HAVCR2 | PPIA 851/4885LMNA 821/4885HTT 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.